Experience of Mycophenolate Mofetil in 10 Patients With Autoimmune-Related Interstitial Lung Disease Demonstrates Promising Effects

Section of Rheumatology, Department of Internal Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70115, USA.
The American Journal of the Medical Sciences (Impact Factor: 1.39). 04/2009; 337(5):329-35. DOI: 10.1097/MAJ.0b013e31818d094b
Source: PubMed


Interstitial lung disease (ILD) is a frequent manifestation of connective tissue disease (CTD), especially systemic sclerosis (SSc), polymyositis-dermatomyositis, and rheumatoid arthritis. ILD related to CTDs heralds a poor prognosis and is associated with high mortality and 60% of patients have evidence of ILD. Cyclophosphamide (CYC) is extensively used in SSc ILD with moderate initial response but a poor long-term outcome, and is associated with significant toxicity.
Mycophenolate mofetil (MMF) was administered to 10 patients with autoimmune-related ILD: 4 with SSc, 3 with rheumatoid arthritis, 2 with polymyositis, and 1 with systemic lupus erythematosus and Sjögren syndrome. Five patients received remote CYC infusion. Ten patients had improvement in alveolitis, symptoms (cough, dyspnea, and chest discomfort), perceived quality of life and activity levels. Four of 5 patients discontinued oxygen. Two of 8 repeat high-resolution computed tomography improved, 6 stabilized, none worsened. Pulmonary function testing in 1 of 9 patients showed worsening, 3 with improvement and 5 stabilized. Serial echocardiograms revealed no new pulmonary arterial hypertension and no worsening of preexisting pulmonary arterial hypertension. Very importantly, averaged prednisone dose decreased from 58 to 1.4 mg without worsening.
MMF is safe, well tolerated, and allows reduction or discontinuation of prednisone without worsening of symptoms or objective progression of disease. MMF is less toxic and its targeted antifibrotic properties make it a potentially more effective agent than CYC that may supplant it as a first-line agent or provide sensible post-CYC maintenance or synergistic strategy in the treatment of CTD-ILD.

18 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: La dermatomiositis (DM) es una enfermedad inflamatoria rara que incluye una afectación cutánea constante y una afectación muscular inconstante que predomina en las cinturas. La DM plantea problemas diagnósticos, nosológicos y terapéuticos. Aunque la clínica muscular con afectación predominante en las cinturas es similar en la dermatomiositis y la polimiositis (PM), existen diferencias clínicas, histológicas y fisiopatológicas entre DM y PM. Además, el riesgo de cáncer, claramente bastante mayor en la DM, no aumenta o aumenta poco en la PM. Las diferentes formas clínicas de la DM (DM juvenil, DM amiopática, DM asociada a cáncer, DM asociadas a las colagenosis, síndrome de las antisintetasas), las complicaciones y las posibilidades terapéuticas son discutibles.
    01/2011; 45(2):1–12. DOI:10.1016/S1761-2896(11)71043-3
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bei konsequentem Screening weisen ca. 40 % der Patienten mit einer Polymyositis/Dermatomyositis (PM/DM) Zeichen einer interstitiellen Lungenkrankheit auf. In der Mehrzahl der Fälle handelt es sich dabei um eine „non-specific interstitial pneumonia“, einen histopathologischen Typ, der initial durch ein Entzündungsbild charakterisiert ist und einer immunsuppressiven Therapie zugänglich ist. Die Diagnose der interstitiellen Lungenkrankheit (ILD) im entzündlichen Frühstadium wird unterstützt durch die Autoantikörperbestimmung (mehrheitlich Antisynthetaseantikörper), die differenzierte Spirometrie und die Dünnschicht-Computertomographie. Die Wertigkeit dieser Techniken für die Früherkennung und Prognoseabschätzung wird dargestellt, und die derzeit ausschließlich empirischen Therapieoptionen werden erläutert.
    Zeitschrift für Rheumatologie 04/2013; 72(3). DOI:10.1007/s00393-012-1079-4 · 0.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper describes the utility of the Java-DSP (J-DSP) technology and the associated on-line laboratories in linear systems courses. J-DSP originally was developed for use in a DSP undergraduate course. Recently the functionality of J-DSP has been extended to support communications, image processing and controls courses. In addition, several new functions have been developed to support advanced DSP applications, such as, speech coding, voice recognition, and spectral estimation. Some of these extensions have also been used to demonstrate the use of DSP in emerging research areas such as Genomics. The first part of the paper discusses these functionality extensions and planned functionality and the second part focuses on the on-line J-DSP laboratories and assessment of J-DSP labs.
    Signals, Systems and Computers, 2003. Conference Record of the Thirty-Seventh Asilomar Conference on; 12/2003
Show more